SCHEMBL2644905

SCHEMBL2644905

COC(=O)c1ccc(/C=N/NC(=O)O)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.71
KDM4E B2RXH2 3/20 0.65
KMT2A Q03164 3/20 0.63
L3MBTL1 Q9Y468 2/20 0.63
HTT P42858 1/20 0.63
MAPT P10636 4/20 0.61
LMNA P02545 2/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2C9 P11712 1/20 0.61
CYP2C19 P33261 1/20 0.61
SMN1; SMN2 Q16637 2/20 0.60
POLB P06746 2/20 0.60
NPC1 O15118 2/20 0.60
RAB9A P51151 2/20 0.60
GAA P10253 2/20 0.60
CTDSP1 Q9GZU7 1/20 0.60
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
ALDH1A1 P00352 3/20 0.58
MEN1 O00255 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2644908 1.00 CYP1A2 (0.71) CYP1A2KDM4EKMT2AL3MBTL1HTT
SCHEMBL16182575 0.88 LMNA (0.80) CYP1A2KDM4EKMT2AL3MBTL1HTT
SCHEMBL22922223 0.87 KDM4E (0.62) CYP1A2KDM4EKMT2AL3MBTL1HTT
SCHEMBL15672277 0.85 MIF (0.72) CYP1A2KDM4EKMT2AL3MBTL1HTT
SCHEMBL15672285 0.83 KDM4E (0.73) CYP1A2KDM4EKMT2AL3MBTL1HTT
SCHEMBL2491390 0.83 CYP1A2 (1.00) CYP1A2KMT2AL3MBTL1HTTMAPT
SCHEMBL2491393 0.83 CYP1A2 (1.00) CYP1A2KMT2AL3MBTL1HTTMAPT
SCHEMBL4172197 0.81 MAPT (0.70) KDM4EKMT2AL3MBTL1HTTMAPT
SCHEMBL4172201 0.81 MAPT (0.70) KDM4EKMT2AL3MBTL1HTTMAPT
SCHEMBL738324 0.80 RAB9A (0.70) KDM4EKMT2AL3MBTL1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7799818-B2 Pyrazole derivatives, compositions containing such compounds and methods of use MERCK SHARP & DOHME CORP. (US) 2010-09-21 US disclosed
EP-1773330-B1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME (US) 2010-05-26 EP disclosed
US-7649009-B2 N-(trans-4-tert-butylcyclohexyl)-1-{4-[(1h-tetrazol-5-ylamino)carbonyl]benzyl }-3-(3,4,5-trifluoropbenyl)-1h-pyrazole-5-carboxamide; type 2 diabetes, hyperglycemia, diabetes or insulin resistance, Syndrome X, atherosclerosis MERCK & CO., INC. (US) 2010-01-19 US disclosed
US-7625938-B2 Substituted pyrazoles, compositions containing such compounds and methods of use MERCK & CO., INC. (US) 2009-12-01 US disclosed
EP-1765335-B1 PYRAZOLE AMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO INC (US) 2009-11-25 EP disclosed
US-7598285-B2 Pyrazole derivatives, compositions containing such compounds and methods of use MERCK & CO., INC (US) 2009-10-06 US disclosed
US-20090176854-A1 N-[4-((1S)-1-{3-(3,5-Dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthyl]-1H-pyrazol-1-yl}ethyl)benzoyl]- beta -alanine; type 2 diabetes, hyperglycemia, or insulin resistance MERCK SHARP & DOHME LLC 2009-07-09 US disclosed
EP-1756064-B1 PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO INC (US) 2008-05-14 EP disclosed
US-20080108620-A1 Substituted Pyrazoles, Compositions Containing such Compounds and Methods of Use MERCK & CO., INC. (US) 2008-05-08 US disclosed
US-20070203186-A1 Pyrazole Amide Derivatives, Compositions Containing Such Compounds And Methods Of Use MERCK & CO., INC. (US) 2007-08-30 US disclosed
CN-1980665-A Pyrazole amide derivatives, compositions containing such compounds and methods of use MERCK & CO INC (US) 2007-06-13 CN disclosed
US-20050272794-A1 Pyrazole derivatives, compositions containing such compounds and methods of use MERCK SHARP & DOHME LLC 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272794-A1 Pyrazole derivatives, compositions containing such compounds and methods of use PC, GOT2, PNLIP CYP1A2 84/4885KDM4E 4338/4885KMT2A 4218/4885
US-20080108620-A1 Substituted Pyrazoles, Compositions Containing such Compounds and Methods of Use GLP1R, GCGR, GPR119 CYP1A2 357/4885KDM4E 3476/4885KMT2A 3728/4885
US-20070203186-A1 Pyrazole Amide Derivatives, Compositions Containing Such Compounds And Methods Of Use AADAC, GOT2, GLS2 CYP1A2 69/4885KDM4E 3512/4885KMT2A 3156/4885
US-20090176854-A1 N-[4-((1S)-1-{3-(3,5-Dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthyl]-1H-pyrazol-1-yl}ethyl)benzoyl]- beta -alanine; type 2 diabetes, hyperglycemia, or insulin resistance GOT2, GOT1, IAPP CYP1A2 281/4885KDM4E 4387/4885KMT2A 3960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.